Prevalence of *Chlamydia trachomatis* in urine of male patients with ankylosing spondylitis is not increased

M van der Paardt, J C van Denderen, A J C van den Brule, S A Morré,
I E van der Horst-Bruinsma, P D Bezemer, B A C Dijkmans

Abstract

Objective—To compare the prevalence of *Chlamydia trachomatis* infections in ankylosing spondylitis (AS) patients with controls, using DNA amplification assays in urine specimens.

Methods—The prevalence of *C trachomatis* infections was assessed in 32 male AS patients and 120 age and sex matched controls. Urine specimens were tested by ligase chain reaction and polymerase chain reaction. In addition, blood samples of AS patients were tested on serum antibodies to *C trachomatis* (IgA and IgG) by a specific peptide based solid phase enzyme immunoassay. A questionnaire was used to assess the differences in sexual behaviour and ethnic origin between the two groups. AS patients were also asked about disease characteristics.

Results—No significant differences were found between cases and controls in the prevalence of *C trachomatis* infections. No associations were found between *C trachomatis* antibodies and disease characteristics, except for acute anterior uveitis (AAU). Four of eight (50%) AS men positive for IgG had a history of AAU in comparison with three of 24 (12.5%) IgG negative men (OR = 7.0; 95% confidence intervals: 1.1, 44.1).

Conclusion—The prevalence of *Chlamydia trachomatis* infections, as detected by commercially available DNA amplification assays in urine specimens, in AS patients is not higher compared with male controls of the same age. However, there seems to be an association between specific antibodies to *C trachomatis* and AAU.

(Ann Rheum Dis 2000;59:300–302)

Recently, commercially available DNA amplification assays—ligase chain reaction (LCR) and polymerase chain reaction (PCR)—have been introduced for the detection of *Chlamydia trachomatis*. These assays have higher sensitivities (90%–95%) and specificities (>99%) for the detection of *C trachomatis* in urine specimens compared with the conventionally used assays of urethra swabs, culture (65%–80% and 100%, respectively) and enzyme immunoassay (60%–85% and 99%, respectively).^{4, 5} This development makes the LCR and PCR a valuable, reliable and painless tool to investigate *C trachomatis* in groups of interest.^{6–8}

The objective of this study was to compare the prevalence of *C trachomatis* infections in AS patients with controls, using commercially available DNA amplification assays in urine specimens.

Methods

Cases were male AS patients, according to the Modified New York Criteria,⁹ visiting the outpatient clinics of the Jan van Breemen Institute and the University Hospital Vrije Universiteit. Inclusion criteria were: age between 20–40 years (most sexually active period), disease duration—as defined by the diagnosis of a rheumatologist—of at most 10 years (to limit the possibility of an infection after onset of AS) and being a resident of Amsterdam (for comparison with the controls).

Controls were men in the same age group from the general population of Amsterdam. The controls were obtained by a random sample from the cohort of a current study dealing with the systematic screening for asymptomatic urogenital infections with *C trachomatis* in men and women in general practice.¹⁰ This survey comprised a random sample of men and women, aged 15–40 years, selected in such a way that the sample reflected the population of Amsterdam.

This study was approved by the ethical committees of the participating hospitals. After informed consent, each participant was sent a questionnaire on demographic characteristics and sexual behaviour, including the use of condoms. Moreover AS patients were also asked about disease characteristics, with emphasis on arthritis, achillotendinitis, cardiac involvement and uveitis. All participants were asked to collect in a container 20 ml first stream and first voided urine. The urine specimens were tested by DNA amplification assays, LCR (LCx, Abbott Laboratories, Chicago, IL, USA) and

Jan van Breemen
Institute, Amsterdam,
the Netherlands
M van der Paardt
J C van Denderen
B A C Dijkmans

Department of
Rheumatology,
University Hospital
Vrije Universiteit,
Amsterdam
M van der Paardt
I E van der
Horst-Bruinsma
B A C Dijkmans

Department of
Pathology, University
Hospital Vrije
Universiteit,
Amsterdam
A J C van den Brule
S A Morré

Department of
Epidemiology and
Biostatistics,
University Hospital
Vrije Universiteit,
Amsterdam
P D Bezemer

Correspondence to:
Dr van der Horst-Bruinsma,
University Hospital Vrije
Universiteit, PO Box 7057,
1007 MB Amsterdam, the
Netherlands

Accepted for publication
16 December 1999

Ankylosing spondylitis (AS) and reactive arthritis (ReA) are closely related disorders. Whereas a gastrointestinal or an urogenital infection is almost by definition considered to provoke ReA, the causative role of an infectious agent in AS is still a matter of debate.

The role of *Chlamydia trachomatis* in ReA has been established, while its role in the pathogenesis of AS remains unclear. German studies report a prevalence of 15%–20% *Chlamydia trachomatis* infections, as detected in urethra swabs, in male AS patients^{1–3}; however, information from controls and confirmation from other laboratories is lacking.

Table 1 Prevalence of an infection with *Chlamydia trachomatis* in patients with ankylosing spondylitis and controls*

	Group		p Value
	Patients (n=32)	Controls (n=120)	
Infection with <i>C trachomatis</i>	1	3	
Prevalence of <i>C trachomatis</i> (95% CI)	3.1% (0.1, 16.2%)	2.5% (0.5, 7.2%)	1.0†
Prevalence of <i>C trachomatis</i> (direct standardisation by age)	2.5%	2.5%	

**C trachomatis* detected by LCx and Amplicor in urine specimens; no differences in positivity were found in samples tested. †Fisher's exact test.

PCR (Amplicor, Roche Diagnostic Systems, Basel, Switzerland). In addition, blood samples were obtained from AS patients to assess serum antibodies to *C trachomatis* (IgA and IgG) by a specific peptide based solid phase enzyme immunoassay (Labsystems, Helsinki, Finland).

The prevalences of the *C trachomatis* infections were compared between cases and controls. As the prevalence of *C trachomatis* infections decreases gradually with age,¹⁰ the prevalences were also calculated (directly) standardised for age, with age divided into four quinquennial categories. The control group was used as standard. In addition, the possible confounders sexual behaviour and ethnic origin were compared between cases and controls. To assess the possible differences in proportions we used the χ^2 test or, if needed, Fisher's exact test. Exact confidence intervals for the prevalences were computed, based on the binomial distribution. After logarithmic transformation, the two sample *t* test was used to evaluate the differences in the total number of sexual relations between patients and controls.

Results

Of 450 AS patients 68 fulfilled the inclusion criteria. Of these patients 20 had moved and were thereby lost to follow up. From the 48 remaining patients 32 (66.7%) responded. The 36 eligible AS patients who could not be included did not differ from the 32 responders with regard to ethnic origin, but had a higher age and a longer disease duration of AS.

In the group of 32 responders 28 (82%) patients were HLA-B27 positive. The mean duration of the disease was four years (range: some months to 10 years; SD 2.6), the mean age was 32 years (range: 21 to 40 years; SD 4.5).

The population survey consisted of 1336 (36%) men. For reasons of statistical efficiency, we limited our random sample from this survey to 120 controls, in the same age range as the patients.

No significant difference was found in the prevalence of *C trachomatis* in urine specimens between patients and controls, using the commercially available DNA assays; the unstandardised and standardised prevalences were identical (table 1). Between LCR and PCR no differences were found in positivity in the samples tested. No significant difference was found between cases and controls with regard to the age distribution, as divided into four quinquennial categories. Comparing the possible confounders no significant differences were found between cases and controls with regard to sexual disposition, marital status, new sexual relationships two months before our study, the

total number of different sexual relationships six months before our study, the total number of different sexual relationships in the past and the use of condoms. With regard to the ethnic origin the patient group was significantly different ($p < 0.01$) from the control group in the number of Turkish men, six (18.8%) and four (3.3%), respectively.

In the group of AS patients seven (21.9%), eight (25.0%) and five (15.6%) were positive for *C trachomatis* IgA, IgG and IgA/IgG, respectively. Preliminary analysis showed no associations between *C trachomatis* antibodies and disease characteristics, except for AAU. Four of eight (50.0%) and three of five (60%) AS men positive for IgG and IgA/IgG, respectively, had a history of AAU in comparison with three of 24 (12.5%) IgG negative men (OR = 7.0; 95% CI: 1.1, 44.1) and four of 27 (14.8%) IgA/IgG negative men (OR = 8.6; 95% CI: 1.1, 69.1), respectively.

Discussion

This study did not show a significant difference between 32 AS patients and 120 controls in the prevalence of *C trachomatis* infections, as detected in urine specimens by DNA amplification methods. Based on the data acquired by a questionnaire we concluded that cases and controls were comparable in sexual behaviour, so differences in sexual behaviour did not bias our study. With regard to ethnic origin the percentage of Turkish men was significantly higher among cases than controls. According to data from the Municipal Health Service in Amsterdam, the Turkish inhabitants and the rest of the population are comparable with regard to the prevalence of *C trachomatis* urogenital infections.^{11 12} Therefore it was not likely that this difference biased the outcome of our study either.

Although no increased risk was observed in case of *C trachomatis* infection a causative relation cannot be excluded, but the role of persistent infections with *C trachomatis* becomes less probable.

As the LCR and PCR have higher sensitivities and specificities for the detection of *C trachomatis* in urine specimens compared with the conventionally used assays of urethra swabs,^{4 5} the only explanation for the discrepancy between the results of this study as assessed with LCR and PCR and those of the earlier mentioned German study group¹⁻³ is that the latter also examined prostatic fluid, which might increase the chance of detection. Considering this discrepancy further research in the possible causative role of *C trachomatis* in the pathogenesis of AS remains necessary.

To our knowledge to date there is no publication on the prevalences of specific *C trachomatis* antibodies among men in the general population to compare with the prevalences of the antibodies among AS patients, as found in this study. The association of specific antibodies to *C trachomatis* and AAU needs further research into the possible causative role for *C trachomatis* in the pathogenesis of AAU.

The main conclusion from this study is that the prevalence of *C trachomatis* infections, as detected by the currently available commercially DNA amplification assays, in urine specimens, in AS patients is not higher compared with male controls in the same age group.

The authors wish to thank Irene van Valkengoed, Joan Boeke, Jacques van Eijk and Chris Meijer for supplying the control group.

- 1 Weidner W, Schiefer HG, Schmidt KL. Urogenitale Infektionen bei seronegativer "reactiver" Arthritis und ankylosierender Spondylitis. *Akt Rheumatol* 1982;7:82-5.
- 2 Schiefer HG, Weidner W, Krauss H, Gerhardt U, Schmidt RL. Rheumafactor-negative Arthritis und Infektionen des männlichen Urogenitaltraktes. *Zentrabl Bakteriell Hyg I Abt Orig A* 1983;255:511-7.
- 3 Lange U, Berliner M, Weidner W, Schiefer HG, Schmidt RL, Federlin K. Ankylosierende Spondylitis und Urogenital infection: Urologische Infektionsdiagnostik und Korrelation mit rheumatologischen Befunden. *Z Rheumatol* 1996;55:249-55.
- 4 Schepetiuk S, Kok T, Martin L, Waddell R, Higgins G. Detection of Chlamydia trachomatis in urine samples by nucleic acid tests: comparison with culture and enzyme immunoassays of genital swab specimen. *J Clin Microbiol* 1997;35:3355-7.
- 5 Schachter J. DFA, EIA, PCR, LCR and other technologies; what tests should be used for diagnosis of Chlamydia infections? *Immunol Invest* 1997;26:157-61.
- 6 Lee HH, Chernesky MA, Schachter J, Burczak JD, Andrews WW, Muldoon S, et al. Diagnosis of Chlamydia trachomatis genitourinary infection in women by ligase chain reaction assay of urine. *Lancet* 1995;345:213-16.
- 7 Chernesky MA, Chong S, Jang D, Luinstra K, Sellors J, Mahony JB. Ability of commercial ligase chain reaction and PCR assays to diagnose Chlamydia trachomatis infections in men by testing first-void urine. *J Clin Microbiol* 1997;35:982-4.
- 8 Morré SA, van Valkengoed IG, de Jong A, Boeke AJ, van Eijk JT, Meijer CJ, et al. Mailed home obtained urine specimens: a reliable screening approach for detecting asymptomatic Chlamydia trachomatis infections. *J Clin Microbiol* 1999;37:976-80.
- 9 Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. *Arthritis Rheum* 1984;27:361-8.
- 10 Van Valkengoed IG, Boeke AJ, van den Brule AJ, Morré SA, Dekker JH, Meijer CJ. Systematic screening for asymptomatic Chlamydia trachomatis infections by home obtained mailed urine samples in men and women in general practice. (In Dutch). *Ned Tijdschr Geneesk* 1999;143:672-6.
- 11 Van den Hoek JA, Mulder-Folkerts DK, Coutinho RA, Dukers NH, Buimer M, Doornum GJ. Opportunistic screening for genital infections with Chlamydia trachomatis among the sexually active population of Amsterdam. I. Over 90% participation and almost 5% prevalence. (In Dutch). *Ned Tijdschr Geneesk* 1999;143:668-72.
- 12 van de Laar MJ, Lan J, van Duynhoven YT, Fennema JS, Ossewaarde JM, van den Brule AJ, et al. Differences in clinical manifestations of genital chlamydial infections related to serovars. *Genitourin Med* 1996;72:261-5.